Core Insights - Becton, Dickinson and Company (BDX) has announced a multi-year collaboration with Opentrons Labworks to integrate robotic liquid-handling capabilities into its single-cell multiomics instruments, aiming to automate critical experimental steps for disease research and drug development [1][5][8] - This partnership is expected to enhance BD's Biosciences (BDB) business unit and strengthen its position in the niche market of lab automation [2][8] - Despite the potential benefits of the collaboration, BDX's stock experienced a decline of nearly 1.8% following the announcement [3] Company Performance - BD currently has a market capitalization of $54.19 billion and an earnings yield of 7.8%, which is higher than the industry average of 6.4% [4] - In the last reported quarter, BDX achieved an earnings surprise of 7.6% [4] - Over the past year, BD's shares have decreased by 19.8%, contrasting with a 2.7% rise in the industry and a 17.8% gain in the S&P 500 [10] Partnership Details - The collaboration aims to integrate the BD Rhapsody System with the Opentrons Flex platform, allowing for hands-free workflows in single-cell multiomics experiments [5][6] - An automation-compatible module for the BD Rhapsody System is expected to automate next-generation sequencing library preparation and cell capture [5][6] Industry Prospects - The global sequencing market is projected to grow from $15.54 billion in 2023 to $62.48 billion by 2030, at a CAGR of 22.2%, driven by increasing demand for gene therapy and consumer genomics [7] - The partnership with Opentrons is anticipated to significantly boost BD's business in light of the favorable market conditions [7]

9k+ Digital Media Outlets 270k+ Journalists Opted In Media: Investors: Fallon McLoughlin Adam Reiffe Director, Public Relations Vice President, Investor Relations 201.258.0361 201.847.6927        [email protected] [email protected]     SOURCE BD (Becton, Dickinson and Company) WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers , /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD ...

, /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the enrollment of the first patient in the XTRACTâ"¢ Registry, a prospective, multi- center, single-arm, post-market registry study designed to evaluate the real-world performance of the Rotarexâ"¢ Catheter System in the treatment of patients with peripheral artery disease (PAD) lesions. BD Reaches Major Milestone for Rotarexâ"¢ Catheter System with First Patient Enrolled in XTRACTâ ...

, /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Opentrons Labworks, Inc., recognized worldwide for accessible lab automation with more than 10,000 robotic systems deployed, today announced a multi-year collaboration. Together, BD and Opentrons will integrate robotic liquid-handling capabilities into BD single-cell multiomics instruments, automating critical experimental steps to accelerate and scale disease research and drug development. BD ...

Accessibility StatementSkip Navigation SUMTER, S.C., Oct. 3, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today will commemorate 55 years of manufacturing excellence at its Sumter, South Carolina facility, which throughout its history has been a core site within the Company's extensive U.S. manufacturing footprint. Continue Reading BD Celebrates 55 Years of Manufacturing Excellence and Impact in Sumter, S.C. About BD Vacutainer productsBD ...

Key Takeaways BD teams up with Henry Ford Health to automate medication storage and prescription pickup access.Collaboration centers on deploying BD Rowa Vmax robots at community pharmacies in Michigan.BD sees this as a boost for its Pharmacy Automation business under the MMS unit of BD Medical.Last week, Becton, Dickinson and Company (BDX) , popularly known as BD, announced a pharmacy automation partnership with Henry Ford Health. The tie-up aims to enhance medication storage and prescription delivery, wit ...

Core Insights - BD (Becton, Dickinson and Company) has announced a pharmacy automation partnership with Henry Ford Health to create a future-oriented pharmacy system, focusing on a robotic solution for 24/7 prescription pickup [1][2]. Group 1: Partnership Details - The collaboration will utilize the BD Rowa™ Vmax, a high-capacity pharmacy automation robot, to improve prescription retrieval processes at Henry Ford Health's community pharmacies in Southeast and Central Michigan [2][3]. - This partnership aims to enhance patient-centered care and innovation within the health system pharmacy [3][4]. Group 2: Benefits of Automation - The BD Rowa™ Vmax is designed for high-speed, modular storage and dispensing of medications, which will improve patient access to prescriptions and streamline pharmacy operations [3][6]. - Key benefits include 24/7 prescription access, real-time tracking, and improved efficiency for pharmacy staff, allowing them to focus on higher-value patient care tasks [6][4]. Group 3: Company Overview - BD is one of the largest global medical technology companies, dedicated to advancing health through innovative technologies and solutions that enhance clinical therapy and care delivery [5][7]. - The company employs over 70,000 individuals and collaborates globally to address significant health challenges, aiming to improve outcomes and lower costs in healthcare [5][7].

Group 1 - Becton, Dickinson and Company (BDX) is recognized as a medical technology company currently undergoing a turnaround due to past challenges, including strategic missteps and a significant product recall [2][3] - The company has acquired the critical care product group from Edwards Lifesciences to enhance its core business and plans to spin off its biosciences and diagnostic solutions division, which is set to be purchased by Waters in a deal expected to close by 2026 [3] - BDX has a strong dividend history, with a 53-year track record of consistent payments, offering a quarterly dividend of $1.04 per share and a dividend yield of 2.22% as of September 19 [5] Group 2 - The planned spinoff of the biosciences and diagnostic solutions division is projected to be accretive to earnings in its first year, suggesting that the dividend should remain stable throughout the transition [4]

Core Insights - BD (Becton, Dickinson and Company) has successfully placed its 1,000th BD Rhapsody™ System at Addenbrooke's Hospital, marking a significant milestone in the adoption of its single-cell multiomics analysis technology [1][2]. Company Overview - BD is recognized as one of the largest global medical technology companies, focusing on improving medical discovery, diagnostics, and care delivery [5]. - The company employs over 70,000 individuals and operates in virtually every country, partnering with organizations to tackle global health challenges [5]. Product Highlights - The BD Rhapsody™ System, introduced in 2017, has been cited in over 700 peer-reviewed publications, demonstrating its impact in the scientific community [2]. - The latest version of the BD Rhapsody™, launched in 2023, features advanced sample processing and cell capture technologies, enhancing the efficiency of next-generation sequencing applications [2]. - Upcoming innovations include the BD OMICS-One™ WTA Next Assay for unlocking genetic information at a lower cost and BD® OMICS-Guard Cryo for sample preservation [6]. Market Demand - The rapid adoption of the BD Rhapsody™ System reflects a critical need for high-performing multiomic assays that maintain data quality while being cost-effective [3]. - The system is positioned to work seamlessly with leading cell sorters and analyzers, indicating a comprehensive end-to-end solution for single-cell analysis [3]. Research and Development - Research conducted by Dr. Andrew Conway Morris at Addenbrooke's Hospital aims to understand immune cell signaling pathways, with the BD Rhapsody™ System facilitating advanced analysis at the single-cell level [2]. - The company continues to innovate its workflows and product offerings to meet the evolving scientific needs [3]. Upcoming Events - The BD Rhapsody™ System will be showcased at the 2025 Annual Meeting of the American Society of Human Genetics and at Advancing Precision Medicine [4].

Dividend Announcements - Alphabet, Becton, Dickinson, and Rogers Communications will trade ex-dividend on 9/8/25 for their upcoming dividends [1] - Alphabet will pay a quarterly dividend of $0.21 on 9/15/25, Becton, Dickinson will pay $1.04 on 9/30/25, and Rogers Communications will pay $0.50 on 10/3/25 [1] Expected Price Adjustments - Alphabet's dividend represents approximately 0.09% of its recent stock price of $231.10, leading to an expected price drop of 0.09% on 9/8/25 [2] - Becton, Dickinson is expected to open 0.55% lower, while Rogers Communications is expected to open 1.40% lower, all else being equal [2] Historical Dividend Analysis - Historical dividend data can provide insights into the stability of future dividends, which is crucial for assessing annual yield expectations [7] - Current estimated annualized yields are 0.36% for Alphabet, 2.20% for Becton, Dickinson, and 5.60% for Rogers Communications [7] Market Performance - On the day of the report, Alphabet shares are up about 9%, Becton, Dickinson shares are up about 0.7%, and Rogers Communications shares are up about 0.4% [8]